ArticleDrug delivery2018
Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogenesis.
Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Clinical Evidence of Traditional Medicines in Modulating the Immune Response and Diabetic Wound Healing.Current topics in medicinal chemistry · 2026Pooled it
- Research progress and insights on the role of ferroptosis in wound healing.International wound journal · 2023Pooled it
- In Vitro Evaluation of Novel Synthetic Benzimidazolium-Chalcone Hybrids: Antioxidant and Regenerative Effects in Diabetic Wound Healing.Applied biochemistry and biotechnology · 2026Article
- Targeting angiogenesis in diabetic wound healing: New insight from chemical architecture to functional outcomes.Journal of pharmaceutical analysis · 2026Review
- Article
- Innovations in hydrogel therapies for diabetic wound healing: bridging the gap between pathophysiology and clinical application.Burns & trauma · 2025Review
- Apoptosis and Cell Clearance in Skin Wound Healing.Advances in experimental medicine and biology · 2025Review
- Insights into the pro-angiogenic effect of hydroxysafflor yellow A (HSYA): targeting HIF-1α and MMP9 in HMEC-1.Frontiers in chemistry · 2025Article
- Orientin promotes diabetic wounds healing by suppressing ferroptosis via activation of the Nrf2/GPX4 pathway.Food science & nutrition · 2024Article
- Safflower Improves Memory, Learning, and Behavior in Rats Subjected to Sleep Deprivation.Cureus · 2024Article
- Transplantation of human endometrial perivascular stem cells with hydroxy saffron yellow A promotes uterine repair in rats.Stem cell research & therapy · 2024Article
- Translational Challenges in Drug Therapy and Delivery Systems for Treating Chronic Lower Extremity Wounds.Pharmaceutics · 2024Review
- Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis.Molecules (Basel, Switzerland) · 2024Review
- Deferoxamine topical cream superior to patch in rescuing radiation-induced fibrosis of unwounded and wounded skin.Journal of cellular and molecular medicine · 2024Article
- Review
- Hydroxysafflor Yellow A Promotes HaCaT Cell Proliferation and Migration by Regulating HBEGF/EGFR and PI3K/AKT Pathways and Circ_0084443.Chinese journal of integrative medicine · 2024Article
- Recent advances in molecular mechanisms of skin wound healing and its treatments.Frontiers in immunology · 2024Review
- Relationship between ferroptosis and healing of diabetic foot ulcer: a prospective clinical study.Frontiers in endocrinology · 2024Article
- Deferoxamine attenuates visual impairment in retinal ischemia‒reperfusion via inhibiting ferroptosis.Scientific reports · 2023Article
- Exploration of the common pathogenic link between COVID-19 and diabetic foot ulcers: An in silico approach.Health science reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonhealing chronic wounds on foot induced by diabetes is a complicated pathologic process. They are mainly caused by impaired neovascularization, neuropathy, and excessive inflammation. A strategy, which can accelerate the vessel network formation as well as inhibit inflammatory response at the same time, makes it possible for effective diabetic ulcers treatment. Co-delivery of multiple drugs with complementary bioactivity offers a strategy to properly treat diabetic wound. We previously demonstrated that hydroxysafflor yellow A (HSYA) could accelerate diabetic wound healing through promoting angiogenesis and reducing inflammatory response. In order to further enhance blood vessel formation, a pro-angiogenic molecular called deferoxamine (DFO) was topically co-administrated with HSYA. The in vitro results showed that the combination of DFO and HSYA exerted synergistic effect on enhancing angiogenesis by upregulation of hypoxia inducible factor-1 alpha (HIF-1α) expression. The interpenetrating polymer networks hydrogels, characterized by good breathability and water absorption, were designed for co-loading of DFO and HSYA aiming to recruit angiogenesis relative cells and upgrade wound healing in vivo. Both DFO and HSYA in hydrogel have achieved sustained release. The in vivo studies indicated that HSYA/DFO hydrogel could accelerate diabetic wound healing. With a high expression of Hif-1α which is similar to that of normal tissue. The noninvasive US/PA imaging revealed that the wound could be recovered completely with abundant blood perfusion in dermis after given HSYA/DFO hydrogel for 28 days. In conclusion, combination of pro-angiogenic small molecule DFO and HSYA in hydrogel provides a promising strategy to productively promote diabetic wound healing as well as better the repair quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.